MaxCyte unveils ExPERT DTx(TM), a 96-well electroporation platform to accelerate discovery
MWN-AI** Summary
MaxCyte, Inc. (NASDAQ: MXCT), a leader in cell engineering, has announced its latest innovation: the ExPERT DTx™, a 96-well electroporation platform designed to accelerate research and drug discovery processes. Launched on February 24, 2026, the ExPERT DTx integrates a modular and high-throughput system that transfects primary cells and cell lines with minimal stress. This approach aims to enhance researchers' understanding of biological processes before scaling up to larger transfection volumes.
The ExPERT DTx platform allows for the processing of up to 96 samples in a mere three minutes, utilizing its R-50x96™ well processing assembly, which is touted as one of the most cost-effective solutions available for 96-well electroporation today. The design accommodates 12 detachable 8-well strips that can be processed concurrently, each adjustable for different cell and cargo combinations, thus ensuring consistency and flexibility while reducing laboratory waste.
The system has been validated across various applications, including cell and gene therapy development and protein production, ensuring that optimized processes can be seamlessly transferred to other ExPERT instruments. This feature simplifies the transition from research to cGMP-compliant manufacturing without the need for workflow reoptimization.
A significant aspect of the ExPERT DTx is its user-friendly software, which allows remote experiment design and workflow uploads, maximizing laboratory efficiency. MaxCyte's CEO, Maher Masoud, expressed enthusiasm for the platform, emphasizing its ability to provide deep insights into cellular experiments, ultimately aiding researchers in developing safe and effective cell therapies.
For further details about the ExPERT DTx, visit MaxCyte’s website. The company has a long-standing commitment to advancing cell engineering, aiming to shape the future of medicine through innovative technologies and collaborative efforts.
MWN-AI** Analysis
MaxCyte, Inc. (NASDAQ: MXCT) has recently unveiled its ExPERT DTx™, a cutting-edge 96-well electroporation platform designed to revolutionize the field of cell engineering by streamlining research and drug discovery. This new system offers researchers a substantial enhancement in processing efficiency, capable of transfecting up to 96 samples in just three minutes while minimizing cellular stress. This attribute is particularly significant for labs focused on high-throughput applications, such as gene therapy development and protein production.
The unique modular setup of the R-50x96™ well processing assembly provides flexibility in handling various cell and cargo combinations, which is an attractive feature for researchers. The elimination of transfection as a variable ensures highly reproducible experimental results, which is critical for institutions striving for reliable findings in their studies.
Given this information, prospective investors should consider the implications of ExPERT DTx™ on MaxCyte's market position. The launch likely strengthens its standing as a leader in cell-engineering technologies, possibly driving increased revenues through expanded customer adoption in labs focused on cell therapies. The product's affordability paired with innovative software that facilitates remote experiment design could lead to higher operational efficiency for research teams, enhancing customer engagement and satisfaction.
On the financial side, MaxCyte’s strong commitment to customer needs and their ongoing innovation suggests a growth trajectory that could translate to robust performance in the long term. However, potential investors should also remain vigilant to market competition as other companies may expedite their R&D efforts to counter MaxCyte's advancements.
In conclusion, the launch of ExPERT DTx™ marks a strategic opportunity for MaxCyte to solidify its market dominance in cell therapies. Investors may want to watch for future quarterly reports to evaluate the product's impact on financials and market share.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
ROCKVILLE, Md., Feb. 24, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced the launch of ExPERT DTx™, a new high throughput transfection platform for research and drug discovery applications. This modular, 96-well electroporation system enables labs to transfect primary cells and cell lines with minimal cellular stress, helping researchers to uncover valuable insights and better understand fundamental biological processes before scaling up to larger transfection volumes.
ExPERT DTx streamlines workflows by processing up to 96 samples in a single, three-minute run. The platform’s R-50x96™ well processing assembly provides one of the most cost-effective solutions for 96-well electroporation on the market, allowing 12 detachable 8-well strips to be processed in parallel with unique parameters for different cell and cargo combinations. This ensures consistent well-to-well performance that effectively eliminates transfection as an experimental variable, while maximizing flexibility and reducing laboratory waste. It has been validated in a range of applications – from cell and gene therapy development to protein production – and enables the transfer of optimized processes to other ExPERT instruments, simplifying scale-up from discovery into cGMP-compliant manufacturing without the need to reoptimize workflows.
One of the defining features of the platform is its efficient and user-friendly software package. The DTx Software controls and monitors the instrument, while the DTx Designer software introduces a distinct advantage over current options on the market, enabling users to design their experiments remotely, then upload the workflow when the system is available for use. This maximizes uptime, and is especially beneficial to labs running multiple, back-to-back experiments.
“We’re extremely excited about the launch of the ExPERT DTx, which builds on the company’s established portfolio of best-in-class electroporation technologies,” said Maher Masoud, Chief Executive Officer of MaxCyte. “This cutting-edge platform provides researchers with deep insights into their experiments, helping them investigate the underlying biology of a cellular system before scaling up operations with confidence. We’ve developed this product around our customers’ needs, giving them the flexibility needed for research while delivering reproducible results with high cell viability at an affordable price.”
For more information about ExPERT DTx, please visit: https://maxcyte.com/electroporation-systems/dtx/
About MaxCyte
At MaxCyte®, we are committed to building better cells together. As a leading cell-engineering company, we are driving the discovery, development and commercialization of next-generation cell therapies. Our best-in-class Flow Electroporation® technology and SeQure DX® gene editing risk assessment services enable precise, efficient and scalable cell engineering. Supported by expert scientific, technical and regulatory guidance, our platform empowers researchers from around the world to engineer diverse cell types and payloads, accelerating the development of safe and effective treatments for human health. For more than 25 years, we’ve been advancing cell engineering, shaping the future of medicine. Learn more at maxcyte.com and follow us on X and LinkedIn.
MaxCyte Contacts:
Investor Relations
Gilmartin Group
David Deuchler, CFA
ir@maxcyte.com
Media Contact
Oak Street Communications
Kristen White
+1 415-608-6060
kristen@oakstreetcommunications.com
FAQ**
How does MaxCyte Inc. (MXCT) plan to leverage the capabilities of the ExPERT DTx platform to enhance its position in the cell therapy market over the next few years?
What specific applications has MaxCyte Inc. (MXCT) validated for the ExPERT DTx platform, and how do these applications align with current trends in drug discovery?
In what ways might the introduction of the ExPERT DTx platform impact MaxCyte Inc. (MXCT)'s financial performance and market competitiveness going forward?
Can you elaborate on how MaxCyte Inc. (MXCT) is addressing customer feedback in the development of the ExPERT DTx platform to ensure it meets researchers’ diverse needs effectively?
**MWN-AI FAQ is based on asking OpenAI questions about MaxCyte Inc. (NASDAQ: MXCT).
NASDAQ: MXCT
MXCT Trading
5.77% G/L:
$1.10 Last:
1,382,133 Volume:
$1.04 Open:
